- Home
- OPFI vs VNDA Comparison
OPFI vs VNDA Comparison
Compare OPFI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- VNDA
- Stock Information
- Founded
- OPFI 2009
- VNDA 2002
- Country
- OPFI United States
- VNDA United States
- Employees
- OPFI N/A
- VNDA N/A
- Industry
- OPFI Finance: Consumer Services
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- VNDA Health Care
- Exchange
- OPFI Nasdaq
- VNDA Nasdaq
- Market Cap
- OPFI 205.2M
- VNDA 237.9M
- IPO Year
- OPFI N/A
- VNDA 2006
- Fundamental
- Price
- OPFI $12.43
- VNDA $3.98
- Analyst Decision
- OPFI Buy
- VNDA Strong Buy
- Analyst Count
- OPFI 2
- VNDA 2
- Target Price
- OPFI $11.75
- VNDA $16.50
- AVG Volume (30 Days)
- OPFI 866.2K
- VNDA 477.8K
- Earning Date
- OPFI 05-07-2025
- VNDA 05-07-2025
- Dividend Yield
- OPFI 1.99%
- VNDA N/A
- EPS Growth
- OPFI N/A
- VNDA N/A
- EPS
- OPFI N/A
- VNDA N/A
- Revenue
- OPFI $305,566,000.00
- VNDA $201,351,000.00
- Revenue This Year
- OPFI $112.50
- VNDA $14.36
- Revenue Next Year
- OPFI $7.84
- VNDA $44.53
- P/E Ratio
- OPFI N/A
- VNDA N/A
- Revenue Growth
- OPFI 31.46
- VNDA 13.37
- 52 Week Low
- OPFI $2.82
- VNDA $3.85
- 52 Week High
- OPFI $17.73
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- OPFI 76.20
- VNDA 35.66
- Support Level
- OPFI $11.30
- VNDA $3.94
- Resistance Level
- OPFI $12.30
- VNDA $4.51
- Average True Range (ATR)
- OPFI 0.50
- VNDA 0.17
- MACD
- OPFI 0.38
- VNDA -0.04
- Stochastic Oscillator
- OPFI 94.31
- VNDA 9.59
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.